News and media
We are pleased to announce that Resyca BV has successfully renewed its ISO 13485 certification, securing validity until 2028. This […]
Soft Mist Nasal Spray Technology Designed to Enhance Drug Deposition in the Olfactory Region, Increasing the Potential for CYR-064’s Therapeutic […]
MDR Certification Strengthens Resyca’s Leadership in Soft Mist Drug-Device Combination Products Download press release: Press Release – Resyca BV receives […]
Now available for licensing, Ultra Soft Nasal Pump Spray leverages innovative spray nozzle chip technology for superior nasal cavity coverage […]
Resyca will be attending CPHI in Milan from October 8-10, 2024, at Fiera Milano Rho, Italy! We are thrilled to […]
Nose-to-Brain Drug Delivery Shows Promising Patient Safety and Therapeutic Benefit The Device and CMC Development Master Plan is designed to […]
Separation Creates Leading Global CDMO Focused on Inhaled and Nasal Drug Delivery Download press release: Press Release 02 Apr 2024 […]
Partnership will help bring breakthroughs in the nasal delivery of fragile biologics and small molecules to market Recipharm, a leading […]
June 15, 2023
June 15, 2023
The new strategic collaboration aims to provide innovative primary packaging to pharmaceutical and biopharmaceutical companies using Resyca®’s proprietary soft mist inhalers.
